156 related articles for article (PubMed ID: 15592724)
21. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
[TBL] [Abstract][Full Text] [Related]
22. Patient page. Multiple sclerosis treatment: some safety issues to keep in mind.
Aguilar M
Neurology; 2004 Feb; 62(4):E8-9. PubMed ID: 14981207
[No Abstract] [Full Text] [Related]
23. Aminotransferase upper reference limits and the prevalence of elevated aminotransferases in the Korean adolescent population.
Park SH; Park HY; Kang JW; Park J; Shin KJ
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):668-72. PubMed ID: 22744190
[TBL] [Abstract][Full Text] [Related]
24. Severe acute hepatitis after resumption of interferon-Beta therapy for multiple sclerosis: a word of caution.
Grieco A; Montalto M; Vero V; Maria Vecchio F; Gasbarrini G
Am J Gastroenterol; 2007 Nov; 102(11):2606-7. PubMed ID: 17958769
[No Abstract] [Full Text] [Related]
25. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM
Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
[TBL] [Abstract][Full Text] [Related]
26. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis.
Kubota S; Amino N; Matsumoto Y; Ikeda N; Morita S; Kudo T; Ohye H; Nishihara E; Ito M; Fukata S; Miyauchi A
Thyroid; 2008 Mar; 18(3):283-7. PubMed ID: 18001177
[TBL] [Abstract][Full Text] [Related]
27. A pre-marketing ALT signal predicts post-marketing liver safety.
Moylan CA; Suzuki A; Papay JI; Yuen NA; Ames M; Hunt CM
Regul Toxicol Pharmacol; 2012 Aug; 63(3):433-9. PubMed ID: 22668747
[TBL] [Abstract][Full Text] [Related]
28. [Survey of anti-tuberculosis drug-induced severe liver injury in Japan].
Shigeto E;
Kekkaku; 2007 May; 82(5):467-73. PubMed ID: 17564126
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
[TBL] [Abstract][Full Text] [Related]
30. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
[TBL] [Abstract][Full Text] [Related]
31. Laboratory assessment of hepatic injury in the woodchuck (Marmota monax).
Hornbuckle WE; Graham ES; Roth L; Baldwin BH; Wickenden C; Tennant BC
Lab Anim Sci; 1985 Aug; 35(4):376-81. PubMed ID: 2864472
[TBL] [Abstract][Full Text] [Related]
32. Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
Muñoz MA; Kulick CG; Kortepeter CM; Levin RL; Avigan MI
Mult Scler; 2017 Dec; 23(14):1947-1949. PubMed ID: 28086032
[TBL] [Abstract][Full Text] [Related]
33. Statins and elevated liver tests: what's the fuss?
Onusko E
J Fam Pract; 2008 Jul; 57(7):449-52. PubMed ID: 18625167
[TBL] [Abstract][Full Text] [Related]
34. Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients.
Tremlett H; Seemüller S; Zhao Y; Yoshida EM; Oger JD; Petkau J
Neurology; 2006 Oct; 67(7):1291-3. PubMed ID: 17030771
[TBL] [Abstract][Full Text] [Related]
35. Liver function tests: what is the risk?
Titcomb CP
J Insur Med; 2003; 35(1):26-35. PubMed ID: 14694823
[TBL] [Abstract][Full Text] [Related]
36. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study.
Atasoy N; Erdogan A; Yalug I; Ozturk U; Konuk N; Atik L; Ustundag Y
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1255-60. PubMed ID: 17600607
[TBL] [Abstract][Full Text] [Related]
37. Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.
Gaetani L; Menduno PS; Cometa F; Di Gregorio M; Sarchielli P; Cagini C; Calabresi P; Di Filippo M
J Neurol; 2016 Mar; 263(3):422-7. PubMed ID: 26292794
[TBL] [Abstract][Full Text] [Related]
38. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
Ambrosy AP; Vaduganathan M; Huffman MD; Khan S; Kwasny MJ; Fought AJ; Maggioni AP; Swedberg K; Konstam MA; Zannad F; Gheorghiade M;
Eur J Heart Fail; 2012 Mar; 14(3):302-11. PubMed ID: 22357577
[TBL] [Abstract][Full Text] [Related]
39. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
[TBL] [Abstract][Full Text] [Related]
40. [Propylthiouracil-induced overt hepatic injury in patients with hyperthyroidism].
Lian XL; Bai Y; Dai WX; Guo ZS; Li W; Lu L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):172-7. PubMed ID: 15171556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
